Mirum Pharmaceuticals showcases LIVMARLI research findings
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and is set to take place in early November. The data focuses on the outcomes and experiences of patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), promising advancements in treating these rare diseases.
Upcoming Presentations Highlighting Clinical Benefits
During the conference, Mirum Pharmaceuticals will present several abstracts demonstrating the efficacy and advantages of LIVMARLI in pediatric patients. These presentations are particularly vital as they shed light on real-world evidence supporting the treatment's benefits. Each session will include data spanning various aspects of patient care and outcomes:
Abstract 77
This study delves into how maralixibat enhances growth in individuals diagnosed with PFIC. The findings will be shared during a dedicated poster session.
Abstract 361
Data presented by Dr. Karen Murray will discuss the durable clinical benefits observed in ALGS patients after extended treatment with maralixibat, highlighting its long-term impact.
Abstract 637
This research outlines the correlation between serum bile acid levels and liver health in children undergoing maralixibat treatment for PFIC, emphasizing the importance of monitoring these factors.
Abstract 638
In another pivotal presentation, improvements in pruritus and their effects on the health-related quality of life for cholestatic liver disease patients following maralixibat treatment will be examined.
Abstract 664
The final abstract reveals insights into the long-term consequences of maralixibat treatment on concomitant medication needs for treating cholestatic pruritus in ALGS, showcasing real-world experiences.
About LIVMARLI® and Its Approval
LIVMARLI® (maralixibat) oral solution functions as an IBAT inhibitor and has received approval from the U.S. Food and Drug Administration, aiming to treat cholestatic pruritus associated with ALGS and PFIC. The medication has been approved for use in patients three months and older in the U.S. and in those two months and older in Europe, providing vital treatment options for young patients suffering from these conditions.
Understanding the Safety of LIVMARLI
The safety profile of LIVMARLI is carefully monitored. It is essential to recognize that the treatment may result in side effects, including liver injury, gastrointestinal disturbances, and vitamin deficiencies. Medical professionals recommend regular liver function tests to mitigate these risks.
Key Safety Considerations
A consideration with LIVMARLI includes its limitation of use for PFIC type 2 patients with severe bile salt export pump (BSEP) deficiencies. Monitoring for liver function and addressing any gastrointestinal issues is critical during treatment.
Mirum Pharmaceuticals: A Leader in Rare Disease Treatments
Mirum Pharmaceuticals is dedicated to developing innovative treatments for rare diseases, with multiple approved medications including LIVMARLI for ALGS and PFIC. The company is committed to expanding its offerings through ongoing clinical trials aimed at enhancing patient care for those with unique medical needs.
With a robust late-stage pipeline, Mirum is exploring new therapeutic avenues that hold promise for additional disorders, underscoring its position at the forefront of rare disease treatment.
Frequently Asked Questions
What is LIVMARLI used to treat?
LIVMARLI is used to treat cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis.
How does LIVMARLI work?
LIVMARLI functions as an ileal bile acid transporter (IBAT) inhibitor, helping to reduce bile salt accumulation in the body.
What are the side effects of LIVMARLI?
Potential side effects include liver injury, gastrointestinal issues, and fat-soluble vitamin deficiencies.
Who is the manufacturer of LIVMARLI?
LIVMARLI is manufactured by Mirum Pharmaceuticals, Inc., which focuses on treatments for rare diseases.
Is LIVMARLI FDA-approved?
Yes, LIVMARLI has received FDA approval for the treatment of cholestatic pruritus in eligible pediatric patients.
